Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 30 articles: HTML format

Single Articles

August 2025
1. ZUO X, Xu J, Yang D, Yang C, et al
   SRSF9 Forms Phase-separated Condensates to Promote Ovarian Cancer Progression by Inducing RNA Alternative Splicing that is Inhibited by m6A Modification.
   Cancer Res. 2025 Aug 7. doi: 10.1158/0008-5472.CAN-24-4233.
   PubMed     Abstract available
   
   
   July 2025
2. VALENTINE MC, Mullen MM, Kotnik EN, Powell MA, et al
   Multi-omic Characterization of Pre- and Post-neoadjuvant Chemotherapy Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response.
   Cancer Res. 2025 Jul 22. doi: 10.1158/0008-5472.CAN-24-3804.
   PubMed     Abstract available
   
   
   
3. NIE H, Liao L, Zielinski RJ, Gomez JA, et al
   Selective Alanine Transporter Utilization is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer.
   Cancer Res. 2025 Jul 14. doi: 10.1158/0008-5472.CAN-25-0654.
   PubMed     Abstract available
   
   
   May 2025
4. RAUPACH EA, Hegde AM, Garcia-Mansfield K, Alcantara M, et al
   Loss of SMARCA4 leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
   Cancer Res. 2025 May 23. doi: 10.1158/0008-5472.CAN-24-0044.
   PubMed     Abstract available
   
   
   
5. ZHU X, Fu Z, Aceto G, St-Germain J, et al
   SMARCA4 loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer.
   Cancer Res. 2025 May 14. doi: 10.1158/0008-5472.CAN-24-3990.
   PubMed     Abstract available
   
   
   
6. ABBASI A, Steele CD, Bergstrom EN, Khandekar A, et al
   HRProfiler Detects Homologous Recombination Deficiency in Breast and Ovarian Cancers Using Whole-Genome and Whole-Exome Sequencing Data.
   Cancer Res. 2025 May 6. doi: 10.1158/0008-5472.CAN-24-2639.
   PubMed     Abstract available
   
   
   April 2025
7. HOCKINGS H, Lakatos E, Huang W, Mossner M, et al
   Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control.
   Cancer Res. 2025 Apr 29. doi: 10.1158/0008-5472.CAN-25-0351.
   PubMed     Abstract available
   
   
   
8. ZHANG C, Wang Y, He M, Wang C, et al
   Mannose Enhances Immunotherapy Efficacy in Ovarian Cancer by Modulating Gut Microbial Metabolites.
   Cancer Res. 2025 Apr 17. doi: 10.1158/0008-5472.CAN-24-3209.
   PubMed     Abstract available
   
   
   
9. DOMMER AP, Kumarasamy V, Wang J, O'Connor TN, et al
   Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222.
   Cancer Res. 2025;85:1310-1326.
   PubMed     Abstract available
   
   
   
10. STOJANOVIC L, Abbotts R, Tripathi K, Coon CM, et al
    ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer.
    Cancer Res. 2025;85:1183-1198.
    PubMed     Abstract available
    
    
    March 2025
11. LAWSON-MICHOD KA, Marks JR, Collin LJ, Nix DA, et al
    Genomic Characterization of High-Grade Serous Ovarian Carcinoma Reveals Distinct Somatic Features in Black Individuals.
    Cancer Res. 2025 Mar 10. doi: 10.1158/0008-5472.CAN-24-1879.
    PubMed     Abstract available
    
    
    
12. WELTE T, Vuttaradhi VK, Khlebus EY, Brodsky A, et al
    Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors.
    Cancer Res. 2025;85:875-893.
    PubMed     Abstract available
    
    
    February 2025
13. HOUSE NC, Brown VE, Chen M, Yuan L, et al
    Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors.
    Cancer Res. 2025 Feb 13. doi: 10.1158/0008-5472.CAN-24-2360.
    PubMed     Abstract available
    
    
    November 2024
14. MANDAL J, Jones TN, Liberto JM, Gaillard S, et al
    Dual Inhibition of SYK and EGFR Overcomes Chemoresistance by Inhibiting CDC6 and Blocking DNA Replication.
    Cancer Res. 2024;84:3881-3893.
    PubMed     Abstract available
    
    
    October 2024
15. DA COSTA AA, Somuncu O, Ravindranathan R, Mukkavalli S, et al
    Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity.
    Cancer Res. 2024;84:3435-3446.
    PubMed     Abstract available
    
    
    August 2024
16. SPEAR S, Le Saux O, Mirza HB, Iyer N, et al
    PTEN loss shapes macrophage dynamics in high grade serous ovarian carcinoma.
    Cancer Res. 2024 Aug 26. doi: 10.1158/0008-5472.CAN-23-3890.
    PubMed     Abstract available
    
    
    May 2024
17. JOY JD, Malacrida B, Laforets F, Kotantaki P, et al
    Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR T cell activity.
    Cancer Res. 2024 May 31. doi: 10.1158/0008-5472.CAN-23-3007.
    PubMed     Abstract available
    
    
    April 2024
18. WATERS JA, Robinson M, Lujano-Olazaba O, Lucht C, et al
    Omental preadipocytes stimulate matrix remodeling and IGF signaling to support ovarian cancer metastasis.
    Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2613.
    PubMed     Abstract available
    
    
    March 2024
19. RAMANARAYANAN V, Oberdoerffer P
    AKTing on R Loops Makes for an ATRactive Target in Ovarian Cancer Therapy.
    Cancer Res. 2024;84:793-795.
    PubMed     Abstract available
    
    
    January 2024
20. HUANG TT, Chiang CY, Nair JR, Wilson KM, et al
    AKT1 interacts with DHX9 to mitigate R-loop-induced replication stress in ovarian cancer.
    Cancer Res. 2024 Jan 19. doi: 10.1158/0008-5472.CAN-23-1908.
    PubMed     Abstract available
    
    
    December 2023
21. HEO J, Kim YN, Shin S, Lee K, et al
    Serial circulating-tumor DNA analysis with a tumor naive next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer.
    Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-1429.
    PubMed     Abstract available
    
    
    October 2023
22. BEDDOWS I, Fan H, Heinze K, Johnson BK, et al
    Cell state of origin impacts development of distinct endometriosis-related ovarian carcinoma histotypes.
    Cancer Res. 2023 Oct 24. doi: 10.1158/0008-5472.CAN-23-1362.
    PubMed     Abstract available
    
    
    
23. ITO I, Yousef AMG, Chowdhury S, Dickson PN, et al
    Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma.
    Cancer Res. 2023;83:3184-3191.
    PubMed     Abstract available
    
    
    September 2023
24. MUKHERJEE D, Previs RA, Haines C, Al Abo M, et al
    Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis.
    Cancer Res. 2023;83:2889-2907.
    PubMed     Abstract available
    
    
    August 2023
25. YU ZC, Li T, Tully E, Huang P, et al
    Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
    Cancer Res. 2023;83:2750-2762.
    PubMed     Abstract available
    
    
    
26. HU C, Nagaraj AB, Shimelis H, Montalban G, et al
    Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
    Cancer Res. 2023;83:2557-2571.
    PubMed     Abstract available
    
    
    May 2023
27. CAO K, Zhang G, Yang M, Wang Y, et al
    Attenuation of sialylation augments antitumor immunity and improves response to immunotherapy in ovarian cancer.
    Cancer Res. 2023 May 12:CAN-22-3260. doi: 10.1158/0008-5472.CAN-22-3260.
    PubMed     Abstract available
    
    
    
28. KELLIHER L, Lengyel E
    Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront.
    Cancer Res. 2023;83:1383-1385.
    PubMed     Abstract available
    
    
    
29. PETRELLI A, Rizzolio S, Pietrantonio F, Bellomo SE, et al
    BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
    Cancer Res. 2023 May 2:OF1-OF12. doi: 10.1158/0008-5472.CAN-22-2620.
    PubMed     Abstract available
    
    
    April 2023
30. LIU Y, Gusev A, Kraft P
    Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations.
    Cancer Res. 2023;83:1191-1202.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.